Literature DB >> 26169963

Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.

Deborah Ayeni1, Katerina Politi2, Sarah B Goldberg3.   

Abstract

Third-generation mutant-specific EGFR tyrosine kinase inhibitors are showing robust clinical activity, particularly in lung cancers harboring the EGFR(T790M) mutation, yet acquired resistance to these agents emerges. Additional mutations in EGFR can confer resistance that, depending on their genomic context, could determine new drug sensitivities of the cancer cells. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26169963      PMCID： PMC4720502          DOI： 10.1158/1078-0432.CCR-15-1211

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

Authors:  Zofia Piotrowska; Matthew J Niederst; Chris A Karlovich; Heather A Wakelee; Joel W Neal; Mari Mino-Kenudson; Linnea Fulton; Aaron N Hata; Elizabeth L Lockerman; Anuj Kalsy; Subba Digumarthy; Alona Muzikansky; Mitch Raponi; Angel R Garcia; Hillary E Mulvey; Melissa K Parks; Richard H DiCecca; Dora Dias-Santagata; A John Iafrate; Alice T Shaw; Andrew R Allen; Jeffrey A Engelman; Lecia V Sequist
Journal:  Cancer Discov       Date:  2015-05-01       Impact factor: 39.397

2.  EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

Authors:  Dalia Ercan; Hwan Geun Choi; Cai-Hong Yun; Marzia Capelletti; Ting Xie; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2015-05-06       Impact factor: 12.531

3.  Rociletinib in EGFR-mutated non-small-cell lung cancer.

Authors:  Lecia V Sequist; Jean-Charles Soria; Jonathan W Goldman; Heather A Wakelee; Shirish M Gadgeel; Andrea Varga; Vassiliki Papadimitrakopoulou; Benjamin J Solomon; Geoffrey R Oxnard; Rafal Dziadziuszko; Dara L Aisner; Robert C Doebele; Cathy Galasso; Edward B Garon; Rebecca S Heist; Jennifer Logan; Joel W Neal; Melody A Mendenhall; Suzanne Nichols; Zofia Piotrowska; Antoinette J Wozniak; Mitch Raponi; Chris A Karlovich; Sarah Jaw-Tsai; Jeffrey Isaacson; Darrin Despain; Shannon L Matheny; Lindsey Rolfe; Andrew R Allen; D Ross Camidge
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

4.  The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

Authors:  Matthew J Niederst; Haichuan Hu; Hillary E Mulvey; Elizabeth L Lockerman; Angel R Garcia; Zofia Piotrowska; Lecia V Sequist; Jeffrey A Engelman
Journal:  Clin Cancer Res       Date:  2015-05-11       Impact factor: 12.531

5.  The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.

Authors:  Nadia Godin-Heymann; Lindsey Ulkus; Brian W Brannigan; Ultan McDermott; Jennifer Lamb; Shyamala Maheswaran; Jeffrey Settleman; Daniel A Haber
Journal:  Mol Cancer Ther       Date:  2008-04       Impact factor: 6.261

6.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

7.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

8.  Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

Authors:  William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus
Journal:  PLoS Med       Date:  2005-02-22       Impact factor: 11.069

9.  Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Authors:  Kenneth S Thress; Cloud P Paweletz; Enriqueta Felip; Byoung Chul Cho; Daniel Stetson; Brian Dougherty; Zhongwu Lai; Aleksandra Markovets; Ana Vivancos; Yanan Kuang; Dalia Ercan; Sarah E Matthews; Mireille Cantarini; J Carl Barrett; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Nat Med       Date:  2015-05-04       Impact factor: 53.440

10.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Authors:  Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397
View more
  12 in total

Review 1.  Drug Resistance to EGFR Inhibitors in Lung Cancer.

Authors:  Osamu Tetsu; Matthew J Hangauer; Janyaporn Phuchareon; David W Eisele; Frank McCormick
Journal:  Chemotherapy       Date:  2016-02-25       Impact factor: 2.544

Review 2.  Renal biopsy-driven molecular target identification in glomerular disease.

Authors:  Maja T Lindenmeyer; Matthias Kretzler
Journal:  Pflugers Arch       Date:  2017-06-29       Impact factor: 3.657

3.  Present and Future Prospect of Small Molecule & Related Targeted Therapy Against Human Cancer.

Authors:  Akshat Pathak; Sanskriti Tanwar; Vivek Kumar; Basu Dev Banarjee
Journal:  Vivechan Int J Res       Date:  2018

Review 4.  Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.

Authors:  M Cabanero; R Sangha; B S Sheffield; M Sukhai; M Pakkal; S Kamel-Reid; A Karsan; D Ionescu; R A Juergens; C Butts; M S Tsao
Journal:  Curr Oncol       Date:  2017-04-27       Impact factor: 3.677

5.  Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFRT790M/C797S Mutants.

Authors:  Shan Li; Tao Zhang; Su-Jie Zhu; Chong Lei; Mengzhen Lai; Lijie Peng; Linjiang Tong; Zilu Pang; Xiaoyun Lu; Jian Ding; Xiaomei Ren; Cai-Hong Yun; Hua Xie; Ke Ding
Journal:  ACS Med Chem Lett       Date:  2022-01-07       Impact factor: 4.345

6.  ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.

Authors:  Merrida A Childress; Stephen M Himmelberg; Huiqin Chen; Wanleng Deng; Michael A Davies; Christine M Lovly
Journal:  Mol Cancer Res       Date:  2018-07-12       Impact factor: 5.852

7.  Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.

Authors:  Zhe Yang; Jinqi Yang; Yedan Chen; Yang W Shao; Xing Wang
Journal:  Target Oncol       Date:  2019-08       Impact factor: 4.493

8.  Exploring the Regulation Mechanism of Xihuang Pill, Olibanum and β-Boswellic Acid on the Biomolecular Network of Triple-Negative Breast Cancer Based on Transcriptomics and Chemical Informatics Methodology.

Authors:  Kailin Yang; Liuting Zeng; Anqi Ge; Tingting Bao; Tao Xu; Xiaobing Xie; Lifang Liu
Journal:  Front Pharmacol       Date:  2020-06-11       Impact factor: 5.810

9.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Minghui Liu; Song Xu; Yuli Wang; Ying Li; Yongwen Li; Hongbing Zhang; Hongyu Liu; Jun Chen
Journal:  Oncotarget       Date:  2016-12-20

10.  Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance.

Authors:  Ilgen Mender; Ryan LaRanger; Krishna Luitel; Michael Peyton; Luc Girard; Tsung-Po Lai; Kimberly Batten; Crystal Cornelius; Maithili P Dalvi; Michael Ramirez; Wenting Du; Lani F Wu; Steven J Altschuler; Rolf Brekken; Elisabeth D Martinez; John D Minna; Woodring E Wright; Jerry W Shay
Journal:  Neoplasia       Date:  2018-07-06       Impact factor: 5.715
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.